Clinical Trials Logo

Clinical Trial Summary

The term 'hypersomnia' describes a group of symptoms that includes severe daytime sleepiness and sleeping long periods of time (more than 10 hours per night). Sometimes, hypersomnia is caused by a problem with the quality of sleep occurring at night, for instance when nighttime sleep is disrupted by frequent breathing pauses. In other cases, however, hypersomnia occurs even when nighttime sleep is of good quality. These cases of hypersomnia are presumed to be a symptom of brain dysfunction, and so are referred to as hypersomnias of central (i.e., brain) origin, or primary hypersomnias.

The causes of most of these primary hypersomnias are not known. However, our group has recently identified a problem with the major brain chemical responsible for sedation, known as GABA. In a subset of our hypersomnia patients, there is a naturally-occurring substance that causes the GABA receptor to be hyperactive. In essence, it is as though these patients are chronically medicated with Valium (or Xanax or alcohol, all substances that act through the GABA system), even though they do not take these medications.

Current treatment of central hypersomnias is limited. For the fraction of cases with narcolepsy, there are FDA-approved, available treatments. However, for the remainder of patients, there are no treatments approved by the FDA. They are usually treated with medications approved for narcolepsy, but sleep experts agree that these medications are often not effective for this group of patients.

Based on our understanding of the GABA abnormality in these patients, we evaluated whether flumazenil (an medication approved by the FDA for the treatment of overdose of GABA medications or the reversal of GABA-based anesthesia) would reverse the GABA abnormality in our patients. In a test tube model of this disease, flumazenil does in fact return the function of the GABA system to normal. The investigators have treated a few patients with flumazenil and most have felt that their hypersomnia symptoms improved with this treatment.

To determine whether flumazenil is truly beneficial for primary hypersomnia, this study will compare flumazenil to an inactive pill (the placebo). All subjects will receive both flumazenil and the placebo at different times, and their reaction times and symptoms will be compared on these two treatments to determine if one is superior. Currently, flumazenil can only be given through an injection into a vein (i.e., intravenously). This study will evaluate this intravenous dosing as well as a new form of flumazenil, which is taken as a lozenge to be dissolved under the tongue. If this study shows that flumazenil is more effective than placebo in the treatment of hypersomnia, it will identify a potential new therapy for this difficult-to-treat disorder.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01183312
Study type Interventional
Source Emory University
Contact
Status Completed
Phase Phase 1/Phase 2
Start date September 2010
Completion date January 2012

See also
  Status Clinical Trial Phase
Recruiting NCT04026958 - Clarithromycin Mechanisms in Hypersomnia Syndromes Phase 2
Completed NCT02512588 - A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Phase 2
Completed NCT03597555 - Sodium Oxybate in Idiopathic Hypersomnia Phase 2/Phase 3
Completed NCT03356938 - The Role of the Circadian System in Neurological Sleep-wake Disorders N/A
Completed NCT03533114 - A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Phase 3
Active, not recruiting NCT03542851 - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Phase 2
Completed NCT05156047 - A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Phase 3
Enrolling by invitation NCT05371483 - Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
Not yet recruiting NCT06252571 - a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial Phase 2
Completed NCT04827329 - Anesthetic Management of Patients With Chronic Sleep Disorders
Recruiting NCT05875974 - Ph4 PSG Combined JZP258-407 Phase 4
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT01146600 - Clarithromycin for the Treatment of Hypersomnia Phase 2
Recruiting NCT04330963 - International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Not yet recruiting NCT05615584 - Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence N/A
Completed NCT04091438 - A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Phase 1
Recruiting NCT05837091 - Low Sodium Oxybate in Patients With Idiopathic Hypersomnia Phase 4
Recruiting NCT05321355 - Mainz Register of Patients With Sleep Disorders
Active, not recruiting NCT05668754 - Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH Phase 2
Not yet recruiting NCT06153615 - Local Sleep in Idiopathic Hypersomnia N/A